Cipla Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Cipla Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 5
Author: Geojit BNP Paribas

Keep track of all breaking news and updates on Cipla Ltd. from all sources in a single place.

Load latest

Cipla Ltd.

17 Dec 2024

1442.20

-2.74%

Cipla shares rise over 2% as Kotak forecasts better days ahead, upgrades rating to buy'

Economic Times

Cipla shares rose by 2.4% to Rs 1,483.40 on Tuesday after Kotak Institutional Equities upgraded the stock from "add" to "buy," with a target price of Rs 1,725. This suggests a potential upside of over 16% from the current levels.

Cipla Ltd. is trading below all available SMAs

Cipla shares gain; Kotak upgrades stock to 'Buy' from 'Add'; check target

Business Standard | 17 Dec 2024

Cipla Ltd.

12 Dec 2024

1442.20

-2.74%

Cipla's inhaled insulin' from US' MannKind Corp adds a layer of convenience' for those with diabetes

Business Line

Recently, India's Central Drugs Standard Control Organisation gave Cipla the approval to exclusively distribute and market Afrezza (human insulin) inhalation powder in India

Cipla Ltd. has an average target of 1707.30 from 11 brokers.

HSBC bullish on Indian pharma stocks for 2025

Economic Times | 12 Dec 2024 1 more

Cipla Ltd.

11 Dec 2024

1442.20

-2.74%

Cipla to bring in inhaled insulin Afreeza from US' MannKind Corporation

Business Line

The Central Drugs Standard Control Organisation (CDSCO) has given Cipla the approval to exclusively distribute and market Afrezza (human insulin) inhalation powder, in India

Cipla Ltd.'s price crossed below 50Day SMA today

Cipla gets approval to market Afrezza insulin inhalation powder in India

Business Standard | 11 Dec 2024

Cipla Ltd.

05 Dec 2024

1442.20

-2.74%

Company Update

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 5th December, 2024 has allotted 1,532 fully paid-up equity shares of INR 2 each, pursuant to exercise of employee stock options/stock appreciation rights under the Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company

pdf

Cipla Ltd.

04 Dec 2024

1442.20

-2.74%

CIPLA LTD

Buy: Cipla Ltd.

Target

Geojit BNP Paribas

Number of FII/FPI investors decreased from 1132 to 1077 in Dec 2024 qtr

Cipla Ltd.

02 Dec 2024

1442.20

-2.74%

Company Update

CIPLA LTD. - 500087 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) …

BSE India

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

pdf

Cipla Ltd.

02 Dec 2024

1442.20

-2.74%

Cipla Promoters Sell 1.72% Stake For Over Rs 2,000 Crore

NDTV Profit

The promoter group held a 31.66% stake in the Mumbai-headquartered company before the sale of equity, while after it, their cumulative holding was reduced to 29.94%.

Cipla Ltd.'s price crossed below 50Day SMA today

Cipla receives unsolicited ESG rating of B+ from SES Research

Business Line | 02 Dec 2024 1 more

Cipla Ltd.

02 Dec 2024

1442.20

-2.74%

SAST

CIPLA LTD. - 500087 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Samina Hamied & Others

pdf